HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

View/Open

Supporting information (63.31Kb)

Date

2017-07

ICR Author

Dowsett, Mitch

Marsden,

Author

Bartlett, JMS

Ahmed, I

Regan, MM

Sestak, I

Mallon, EA

Dell'Orto, P

Thurlimann, B

Seynaeve, C

Putter, H

Van de Velde, CJH

Brookes, CL

Forbes, JF

Viale, G

Cuzick, J

Dowsett, M

Rea, DW

Inhibitor, TA

Show allShow less

Type

Journal Article

Metadata

Show full item record

URI

https://repository.icr.ac.uk/handle/internal/1590

DOI

https://doi.org/10.1016/j.ejca.2017.03.033

Collections

• Breast Cancer Research
• Molecular Pathology

Subject

Breast cancer

HER2

Prediction

Aromatase inhibitor

Meta-analysis

Research team

Endocrinology

Language

eng

Date accepted

2017-04-01

License start date

2017-07

Citation

EUROPEAN JOURNAL OF CANCER, 2017, 79 pp. 129 - 138